H.R. 1576 · 114th Congress
Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
BurgessSponsor7 cosponsors · 2 D, 5 R
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015
What it does: CRS summary · Introduced in House · Mar 24, 2015
Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015
This bill requires the Government Accountability Office (GAO) to study whether generic versions of certain complex drugs or certain biological drugs face significantly different challenges in meeting the approval standards of the Food and Drug Administration (FDA) than generic versions of small-molecule drugs. (Complex drugs and biological drugs can be composed of large molecules that are more difficult to fully characterize than small molecules, so it can be more difficult to demonstrate that generic versions of these drugs are the same as the brand name versions.)
If the GAO determines that these generic drugs face significantly different challenges, then the GAO must also determine: (1) the evidence that should be required to demonstrate that one of these generic drugs is sufficiently similar to the brand name drug in safety, composition, and activity; (2) whether the Federal Food, Drug, and Cosmetic Act should be amended to address the approval of these generic drugs; and (3) whether the FDA should develop a policy document on the evidence that is necessary to obtain approval of these generic drugs.Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015
Latest action (Mar 27, 2015): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Mar 24, 2015
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.